Durga Borkar is an Ophthalmology physician. OpenAlex indexes 102 publications with 2,671 citations (h-index 25).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
840 Walnut St Ste 1020
Philadelphia, PA 191075109
Telephone
800-331-6634Registry record last updated 21 Jul 2022.
Industry payments
18 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Astellas Pharma US IncProgram year20259 payments
- Ocular Therapeutix, Inc.Program year20254 payments
- Genentech USA, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
95.5%Antineovascularisation agents93.2%Faricimab-svoa100%Part B, office-administered≥20 patientsCorticosteroid0.8%Prednisolone Acetate100%Part D≥27 patients+ 4 more classes in this area
Cancer & immunology
3.7%Vascular Endothelial Growth Factor Inhibitor3.7%Aflibercept74%Bevacizumab26%Part B, office-administered≥28 patientsMusculoskeletal
0.8%Cyclooxygenase Inhibitor0.8%Ketorolac Tromethamine100%Part D≥19 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Early Outcomes After Initiation of Faricimab for Neovascular Age-Related Macular Degeneration
Ophthalmic surgery, lasers & imaging retina
2025 - Early Outcomes After Initiation of Faricimab in Patients With Diabetic Macular Edema
Ophthalmic surgery, lasers & imaging retina
2025 - Variations in Electronic Health Record-Based Definitions of Diabetic Retinopathy Cohorts
Ophthalmology Science
2024
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Emily Chew, MD
National Eye Institute
Robert Weinreb, MD
University of California San Diego
Harry Quigley, MD
Johns Hopkins University School of Medicine
Joel Schuman, MD
Wills Eye Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”